Dr. Bright, one of the country’s leading vaccine development experts, was director of the Biomedical Advanced Research and Development Authority, which has led federal efforts to develop a COVID-19 vaccine.
BARDA is expected to play an even larger role in the pandemic response since Congress more than tripled its budget in the most recent stimulus package, according to STAT.
Dr. Bright, who became director in 2016, will move to a narrower role at the National Institutes of Health, where he will work on diagnostics, an NIH spokesperson told STAT.
Gary Disbrow, former deputy director of BARDA, will become acting director, an HHS spokesperson confirmed to STAT.
In a statement to The New York Times, Dr. Bright said he was pressured to direct money toward hydroxychloroquine and that he believes his job transfer “was in response to my insistence that the government invest the billions of dollars allocated by Congress to address the COVID-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit.”
Editor’s note: This article was updated on April 23 at 9 a.m. CDT to reflect new information reported by The New York Times.
More articles on pharmacy:
CVS, UCLA Health unite to free hospital beds for COVID-19 patients
NIH teams up with 16 drugmakers to speed COVID-19 vaccine development
16 recent drug, device recalls
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
